S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Electric Vehicles Can Drive Alcoa Stock Higher
Is Tyson Foods A Buy On Post-Earnings Weakness? 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Pfizer buying spree continues with $5.4B hematology deal
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Sell every Stock except ONE (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Electric Vehicles Can Drive Alcoa Stock Higher
Is Tyson Foods A Buy On Post-Earnings Weakness? 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Pfizer buying spree continues with $5.4B hematology deal
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Sell every Stock except ONE (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Electric Vehicles Can Drive Alcoa Stock Higher
Is Tyson Foods A Buy On Post-Earnings Weakness? 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Pfizer buying spree continues with $5.4B hematology deal
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Sell every Stock except ONE (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Electric Vehicles Can Drive Alcoa Stock Higher
Is Tyson Foods A Buy On Post-Earnings Weakness? 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Pfizer buying spree continues with $5.4B hematology deal
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Sell every Stock except ONE (Ad)
NASDAQ:IMAC

IMAC - IMAC Stock Forecast, Price & News

$1.01
0.00 (0.00%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.95
$1.02
50-Day Range
$0.82
$1.15
52-Week Range
$0.75
$1.65
Volume
100,266 shs
Average Volume
708,132 shs
Market Capitalization
$26.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.02

IMAC MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
198.7% Upside
$3.02 Price Target
Short Interest
Healthy
0.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of IMAC in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.34) to ($0.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

1038th out of 1,293 stocks

Specialty Outpatient Clinics, Not Elsewhere Classified Industry

3rd out of 3 stocks

IMAC stock logo

About IMAC (NASDAQ:IMAC) Stock

IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets decreased their target price on IMAC to $5.50 and set a "na" rating for the company in a research note on Monday, May 16th.

IMAC Stock Performance

NASDAQ:IMAC remained flat at $1.01 during trading hours on Monday. The company had a trading volume of 100,266 shares, compared to its average volume of 708,132. The firm has a fifty day moving average of $0.96 and a 200 day moving average of $0.99. IMAC has a 1-year low of $0.75 and a 1-year high of $1.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.27 and a quick ratio of 1.27.

IMAC (NASDAQ:IMAC - Get Rating) last posted its quarterly earnings results on Friday, May 13th. The company reported ($0.12) EPS for the quarter. IMAC had a negative return on equity of 52.17% and a negative net margin of 75.40%. The company had revenue of $3.90 million during the quarter. On average, research analysts anticipate that IMAC will post -0.34 EPS for the current fiscal year.

Institutional Trading of IMAC

Several institutional investors and hedge funds have recently modified their holdings of IMAC. IAM Advisory LLC bought a new stake in shares of IMAC in the 2nd quarter valued at about $37,000. Resources Investment Advisors LLC. boosted its holdings in IMAC by 130.7% during the first quarter. Resources Investment Advisors LLC. now owns 87,111 shares of the company's stock worth $90,000 after buying an additional 49,354 shares in the last quarter. Finally, Shepherd Kaplan Krochuk LLC boosted its holdings in IMAC by 24.3% during the fourth quarter. Shepherd Kaplan Krochuk LLC now owns 84,550 shares of the company's stock worth $96,000 after buying an additional 16,550 shares in the last quarter. 24.27% of the stock is currently owned by institutional investors.

Receive IMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.

IMAC Stock News Headlines

The Back Company demonstrates strong Q2 growth
See More Headlines
Receive IMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.

IMAC Company Calendar

Last Earnings
5/13/2022
Today
8/08/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Specialty outpatient clinics, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMAC
Fax
N/A
Employees
106
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.02
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$1.75
Forecasted Upside/Downside
+198.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-10,540,000.00
Pretax Margin
-75.40%

Debt

Sales & Book Value

Annual Sales
$14.39 million
Book Value
$0.69 per share

Miscellaneous

Free Float
23,837,000
Market Cap
$26.75 million
Optionable
Not Optionable
Beta
-0.88














IMAC Stock - Frequently Asked Questions

Should I buy or sell IMAC stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IMAC in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IMAC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMAC, but not buy additional shares or sell existing shares.
View IMAC analyst ratings
or view top-rated stocks.

What is IMAC's stock price forecast for 2022?

3 brokerages have issued 12 month target prices for IMAC's stock. Their IMAC share price forecasts range from $1.75 to $5.50. On average, they predict the company's share price to reach $3.02 in the next twelve months. This suggests a possible upside of 198.7% from the stock's current price.
View analysts price targets for IMAC
or view top-rated stocks among Wall Street analysts.

How has IMAC's stock performed in 2022?

IMAC's stock was trading at $1.14 at the beginning of the year. Since then, IMAC stock has decreased by 11.4% and is now trading at $1.01.
View the best growth stocks for 2022 here
.

Are investors shorting IMAC?

IMAC saw a increase in short interest in July. As of July 15th, there was short interest totaling 82,100 shares, an increase of 78.1% from the June 30th total of 46,100 shares. Based on an average trading volume of 806,800 shares, the short-interest ratio is presently 0.1 days. Approximately 0.4% of the shares of the company are short sold.
View IMAC's Short Interest
.

When is IMAC's next earnings date?

IMAC is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our IMAC earnings forecast
.

How were IMAC's earnings last quarter?

IMAC Holdings, Inc. (NASDAQ:IMAC) posted its quarterly earnings data on Friday, May, 13th. The company reported ($0.12) earnings per share for the quarter. The company had revenue of $3.90 million for the quarter. IMAC had a negative trailing twelve-month return on equity of 52.17% and a negative net margin of 75.40%.

What other stocks do shareholders of IMAC own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IMAC investors own include VBI Vaccines (VBIV), Biocept (BIOC), Energy Transfer (ET), iBio (IBIO), McEwen Mining (MUX), OPKO Health (OPK), Advanced Micro Devices (AMD), Amarin (AMRN), Aytu BioPharma (AYTU) and Bionano Genomics (BNGO).

When did IMAC IPO?

(IMAC) raised $4 million in an initial public offering (IPO) on the week of February 11th 2019. The company issued 900,000 shares at a price of $5.00 per share. Dawson James Securities and Cuttone served as the underwriters for the IPO.

What is IMAC's stock symbol?

IMAC trades on the NASDAQ under the ticker symbol "IMAC."

Who are IMAC's major shareholders?

IMAC's stock is owned by many different institutional and retail investors. Top institutional shareholders include Resources Investment Advisors LLC. (0.45%) and IAM Advisory LLC (0.17%). Insiders that own company stock include Jeffrey S Ervin, Matthew C Wallis and Michael D Pruitt.
View institutional ownership trends
.

How do I buy shares of IMAC?

Shares of IMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IMAC's stock price today?

One share of IMAC stock can currently be purchased for approximately $1.01.

How much money does IMAC make?

IMAC (NASDAQ:IMAC) has a market capitalization of $26.75 million and generates $14.39 million in revenue each year.

How many employees does IMAC have?

IMAC employs 106 workers across the globe.

How can I contact IMAC?

IMAC's mailing address is 1605 WESTGATE CIRCLE, BRENTWOOD TN, 37027. The official website for the company is www.imacregeneration.com. The company can be reached via phone at (844) 266-4622 or via email at brets@coreir.com.

This page (NASDAQ:IMAC) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.